SynthesisOncotarget2016
MicroRNA-21 as a potential diagnostic biomarker for breast cancer patients: a pooled analysis of individual studies.
Synthesis in Oncotarget, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 2 syntheses or guidelines pooled it, 35 citations in OpenAlex.
- The diagnostic value of serum miR-21 in patients with ovarian cancer: a systematic review and meta-analysis.Journal of ovarian research · 2022Pooled it
- The diagnostic role of microRNA-34a in breast cancer: a systematic review and meta-analysis.Oncotarget · 2017Pooled it
- Mapping Non-Coding Epimutations in Breast Cancer: Advancing Epigenetics Towards Precision Medicine.Sub-cellular biochemistry · 2026Review
- Dysregulation of MiR-21, MiR-221 and MiR-451 During Neoadjuvant Treatment of Breast Cancer: A Prospective Study.Biomolecules · 2024Observational
- Prognostic and diagnostic values of non-coding RNAs as biomarkers for breast cancer: An umbrella review and pan-cancer analysis.Frontiers in molecular biosciences · 2023Article
- MicroRNAs as Potential Biomarkers in the Differential Diagnosis of Lipomatous Tumors and Their Mimics.International journal of molecular sciences · 2022Article
- MicroRNA-21 deficiency suppresses prostate cancer progression through downregulation of the IRS1-SREBP-1 signaling pathway.Cancer letters · 2022Article
- The Implication of microRNAs as non-invasive biomarkers in 179 Egyptian breast cancer female patients.Oncology research · 2022Article
- Co-treatment with miR-21-5p inhibitor and Aurora kinase inhibitor reversine suppresses breast cancer progression by targeting sprouty RTK signaling antagonist 2.Bioengineered · 2022Article
- The Promising Role of miR-21 as a Cancer Biomarker and Its Importance in RNA-Based Therapeutics.Molecular therapy. Nucleic acids · 2020Review
- Plasma extracellular vesicle‑packaged microRNAs as candidate diagnostic biomarkers for early‑stage breast cancer.Molecular medicine reports · 2019Article
- miR-148b-3p, miR-190b, and miR-429 Regulate Cell Progression and Act as Potential Biomarkers for Breast Cancer.Journal of breast cancer · 2019Article
- MiRNA-21 functions in ionizing radiation-induced epithelium-to-mesenchymal transition (EMT) by downregulating PTEN.Toxicology research · 2019Article
- Interrelation of the Circulating and Tissue MicroRNA-21 with Tissue PDCD4 Expression and the Invasiveness of Iraqi Female Breast Tumors.Indian journal of clinical biochemistry : IJCB · 2019Article
- Clinical utility of circulating non-coding RNAs - an update.Nature reviews. Clinical oncology · 2018Review
- MicroRNA-21: A promising biomarker for the prognosis and diagnosis of non-small cell lung cancer.Oncology letters · 2018Review
- Association of long non-coding RNA GAS5 and miR-21 levels in CD4Experimental and therapeutic medicine · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
MicroRNA-21 (miR-21) has been reported as the potential novel diagnostic biomarker for breast cancer in several studies, but their results were inconsistent. Therefore, we conducted a systematic analysis to evaluate the diagnostic value of miR-21 in detecting breast cancer. A comprehensive electronic and manual search was conducted for relevant literatures through several databases up to November 9, 2015. QUADAS-2 was used to assess the quality of the studies included in the study. All statistical analyses were performed using Meta-Disc 1.4 and Stata 12.0. Eleven studies with a total of 918 breast cancer patients and 613 controls were included. The pooled sensitivity, specificity, positive likelihood ratio (PLR), negative likelihood ratio (NLR), and diagnostic odds ratio (DOR) with their 95% confidence intervals (CIs) were 0.72 (95% CI: 0.69-0.75), 0.80 (95% CI: 0.77-0.83), 3.37 (95% CI: 2.24-5.07), 0.30 (95% CI: 0.19-0.50), and 11.79 (95% CI: 5.23-26.57), respectively. The area under the curve of SROC was 0.8517. In conclusion, our analyses suggested that miR-21 is a promising biomarker in diagnosing breast cancer. For clinical purpose, further large-scale studies are warranted to validate its clinical application.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.